Does the media favor TMCI or RNXT?

In the previous week, Treace Medical Concepts had 6 more articles in the media than RenovoRx. MarketBeat recorded 7 mentions for Treace Medical Concepts and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat Treace Medical Concepts' score of 0.78 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RenovoRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor TLSI or RNXT?

In the previous week, TriSalus Life Sciences had 10 more articles in the media than RenovoRx. MarketBeat recorded 11 mentions for TriSalus Life Sciences and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat TriSalus Life Sciences' score of 0.60 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RenovoRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is STIM or RNXT more profitable?

Neuronetics has a net margin of -19.62% compared to RenovoRx's net margin of -621.71%. Neuronetics' return on equity of -125.11% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% RenovoRx -621.71% -135.11% -101.91%

Does the media prefer STIM or RNXT?

In the previous week, Neuronetics had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for Neuronetics and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat Neuronetics' score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, ELMD or RNXT?

Electromed has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $73.78M 3.13 $5.15M $1.31 21.05 RenovoRx $1.12M 65.68 -$11.17M -$0.31 N/A

Is ELMD or RNXT more profitable?

Electromed has a net margin of 11.34% compared to RenovoRx's net margin of -621.71%. Electromed's return on equity of 15.71% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% RenovoRx -621.71% -135.11% -101.91%

Which has stronger valuation & earnings, PDEX or RNXT?

Pro-Dex has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $77.55M 2.97 $13.66M $4.13 17.42 RenovoRx $1.12M 65.68 -$11.17M -$0.31 N/A

Is PDEX or RNXT more profitable?

Pro-Dex has a net margin of 17.62% compared to RenovoRx's net margin of -621.71%. Pro-Dex's return on equity of 25.13% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 17.62% 25.13% 16.02% RenovoRx -621.71% -135.11% -101.91%

Does the media prefer PDEX or RNXT?

In the previous week, Pro-Dex had 5 more articles in the media than RenovoRx. MarketBeat recorded 6 mentions for Pro-Dex and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat Pro-Dex's score of 1.09 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RenovoRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

RenovoRx (RNXT) Competitors

$1.63 -0.07 (-4.12%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.57 -0.06 (-3.93%)

As of 05:54 AM Eastern

Compare

RNXT vs. TMCI, TLSI, STIM, ELMD, and PDEX

Should you buy RenovoRx stock or one of its competitors? RenovoRx's main competitors and comparable companies include Treace Medical Concepts (TMCI), TriSalus Life Sciences (TLSI), Neuronetics (STIM), Electromed (ELMD), and Pro-Dex (PDEX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does RenovoRx compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Treace Medical Concepts had 6 more articles in the media than RenovoRx. MarketBeat recorded 7 mentions for Treace Medical Concepts and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat Treace Medical Concepts' score of 0.78 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Treace Medical Concepts has a net margin of -28.99% compared to RenovoRx's net margin of -621.71%. Treace Medical Concepts' return on equity of -71.37% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-28.99%	-71.37%	-30.49%
RenovoRx	-621.71%	-135.11%	-101.91%

RenovoRx has lower revenue, but higher earnings than Treace Medical Concepts. RenovoRx is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.38	-$59M	-$0.93	N/A
RenovoRx	$1.12M	65.68	-$11.17M	-$0.31	N/A

Treace Medical Concepts has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Treace Medical Concepts currently has a consensus price target of $5.17, indicating a potential upside of 14.63%. RenovoRx has a consensus price target of $8.50, indicating a potential upside of 421.47%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Treace Medical Concepts beats RenovoRx on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

TriSalus Life Sciences has a net margin of -62.59% compared to RenovoRx's net margin of -621.71%. TriSalus Life Sciences' return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
RenovoRx	-621.71%	-135.11%	-101.91%

RenovoRx has lower revenue, but higher earnings than TriSalus Life Sciences. RenovoRx is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.82	-$39.23M	-$1.30	N/A
RenovoRx	$1.12M	65.68	-$11.17M	-$0.31	N/A

TriSalus Life Sciences has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, TriSalus Life Sciences had 10 more articles in the media than RenovoRx. MarketBeat recorded 11 mentions for TriSalus Life Sciences and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat TriSalus Life Sciences' score of 0.60 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 9.4% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TriSalus Life Sciences presently has a consensus target price of $10.20, suggesting a potential upside of 104.00%. RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 421.47%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

RenovoRx beats TriSalus Life Sciences on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

RenovoRx has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.47	-$39M	-$0.44	N/A
RenovoRx	$1.12M	65.68	-$11.17M	-$0.31	N/A

Neuronetics presently has a consensus price target of $4.67, indicating a potential upside of 62.04%. RenovoRx has a consensus price target of $8.50, indicating a potential upside of 421.47%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Neuronetics had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for Neuronetics and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat Neuronetics' score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Neuronetics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Neuronetics has a net margin of -19.62% compared to RenovoRx's net margin of -621.71%. Neuronetics' return on equity of -125.11% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
RenovoRx	-621.71%	-135.11%	-101.91%

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

RenovoRx beats Neuronetics on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Electromed?

Electromed (NYSE:ELMD) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Electromed has a net margin of 11.34% compared to RenovoRx's net margin of -621.71%. Electromed's return on equity of 15.71% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
RenovoRx	-621.71%	-135.11%	-101.91%

Electromed has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Electromed currently has a consensus target price of $43.75, indicating a potential upside of 58.69%. RenovoRx has a consensus target price of $8.50, indicating a potential upside of 421.47%. Given RenovoRx's higher probable upside, analysts plainly believe RenovoRx is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

40.8% of Electromed shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 10.5% of Electromed shares are owned by company insiders. Comparatively, 9.4% of RenovoRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Electromed has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.13	$5.15M	$1.31	21.05
RenovoRx	$1.12M	65.68	-$11.17M	-$0.31	N/A

In the previous week, RenovoRx had 1 more articles in the media than Electromed. MarketBeat recorded 1 mentions for RenovoRx and 0 mentions for Electromed. RenovoRx's average media sentiment score of 1.92 beat Electromed's score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Electromed	Neutral
RenovoRx	Very Positive

Summary

Electromed beats RenovoRx on 10 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Pro-Dex has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$77.55M	2.97	$13.66M	$4.13	17.42
RenovoRx	$1.12M	65.68	-$11.17M	-$0.31	N/A

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 45.9% of Pro-Dex shares are held by company insiders. Comparatively, 9.4% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pro-Dex had 5 more articles in the media than RenovoRx. MarketBeat recorded 6 mentions for Pro-Dex and 1 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.92 beat Pro-Dex's score of 1.09 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pro-Dex has a net margin of 17.62% compared to RenovoRx's net margin of -621.71%. Pro-Dex's return on equity of 25.13% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	17.62%	25.13%	16.02%
RenovoRx	-621.71%	-135.11%	-101.91%

Pro-Dex currently has a consensus target price of $74.00, suggesting a potential upside of 2.86%. RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 421.47%. Given RenovoRx's higher probable upside, analysts plainly believe RenovoRx is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Pro-Dex has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Pro-Dex beats RenovoRx on 11 of the 16 factors compared between the two stocks.

Get RenovoRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export

Metric	RenovoRx	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$76.72M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-5.26	25.26	274.08	25.69
Price / Sales	65.68	71.56	638.21	78.99
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	10.87	5.78	10.47	6.32
Net Income	-$11.17M	$151.55M	$3.49B	$359.73M
7 Day Performance	-5.78%	-0.01%	-0.67%	0.17%
1 Month Performance	30.40%	-3.53%	-3.17%	-3.27%
1 Year Performance	35.83%	6.37%	15.14%	5.58%

RenovoRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	3.4818 of 5 stars	$1.63 -4.1%	$8.50 +421.5%	+32.5%	$76.72M	$1.12M	N/A	17	Positive News
TMCI Treace Medical Concepts	2.9018 of 5 stars	$4.58 -1.1%	$5.17 +12.9%	-33.7%	$301.11M	$212.69M	N/A	450
TLSI TriSalus Life Sciences	2.3387 of 5 stars	$4.78 +0.2%	$8.67 +81.3%	+2.7%	$293.71M	$45.15M	N/A	102	Trending News Analyst Forecast Gap Up
STIM Neuronetics	3.4622 of 5 stars	$2.80 -3.4%	$4.67 +66.7%	+4.7%	$221.35M	$149.16M	N/A	658
ELMD Electromed	2.3085 of 5 stars	$26.29 -0.4%	$43.75 +66.4%	+15.5%	$220.87M	$73.78M	35.05	197

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNXT) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RenovoRx (RNXT) Competitors

RNXT vs. TMCI, TLSI, STIM, ELMD, and PDEX

How does RenovoRx compare to Treace Medical Concepts?

Summary

How does RenovoRx compare to TriSalus Life Sciences?

Summary

How does RenovoRx compare to Neuronetics?

Summary

How does RenovoRx compare to Electromed?

Summary

How does RenovoRx compare to Pro-Dex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RenovoRx (RNXT) Competitors

RNXT vs. TMCI, TLSI, STIM, ELMD, and PDEX

How does RenovoRx compare to Treace Medical Concepts?

Do institutionals and insiders believe in TMCI or RNXT?

Does the media favor TMCI or RNXT?

Is TMCI or RNXT more profitable?

Which has stronger earnings and valuation, TMCI or RNXT?

Which has more volatility & risk, TMCI or RNXT?

Do analysts rate TMCI or RNXT?

Summary

How does RenovoRx compare to TriSalus Life Sciences?

Is TLSI or RNXT more profitable?

Which has higher earnings & valuation, TLSI or RNXT?

Which has more volatility and risk, TLSI or RNXT?

Does the media favor TLSI or RNXT?

Do institutionals and insiders hold more shares of TLSI or RNXT?

Do analysts recommend TLSI or RNXT?

Summary

How does RenovoRx compare to Neuronetics?

Which has higher earnings & valuation, STIM or RNXT?

Do analysts prefer STIM or RNXT?

Does the media prefer STIM or RNXT?

Which has more risk & volatility, STIM or RNXT?

Is STIM or RNXT more profitable?

Do institutionals & insiders have more ownership in STIM or RNXT?

Summary

How does RenovoRx compare to Electromed?

Is ELMD or RNXT more profitable?

Which has more risk and volatility, ELMD or RNXT?

Do analysts prefer ELMD or RNXT?

Do institutionals and insiders have more ownership in ELMD or RNXT?

Which has preferable earnings and valuation, ELMD or RNXT?

Does the media prefer ELMD or RNXT?

Summary

How does RenovoRx compare to Pro-Dex?

Which has stronger valuation & earnings, PDEX or RNXT?

Do institutionals & insiders believe in PDEX or RNXT?

Does the media prefer PDEX or RNXT?

Is PDEX or RNXT more profitable?

Do analysts prefer PDEX or RNXT?

Which has more risk & volatility, PDEX or RNXT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools